BMO Capital Maintains Outperform on Amgen, Raises Price Target to $355
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman maintains an Outperform rating on Amgen (NASDAQ:AMGN) and raises the price target from $336 to $355.
May 03, 2024 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital maintains an Outperform rating on Amgen and raises the price target from $336 to $355.
The increase in price target by BMO Capital suggests a positive outlook on Amgen's stock, likely due to strong performance or positive future expectations. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100